MM120
TopicHeard in 1 episode across 1 show since Jul 2026
MM120 (also known as DT120 or lysergide D-tartrate) is an investigational, pharmacologically optimized formulation of lysergic acid diethylamide (LSD) developed by Definium Therapeutics (formerly MindMed). It is a non-selective serotonin receptor agonist and classic psychedelic being evaluated in clinical trials for the treatment of generalized anxiety disorder (GAD) and major depressive disorder (MDD). In 2024, the United States Food and Drug Administration (FDA) designated MM120 as a breakthrough therapy for GAD.
Episodes
First heard
Expert statements
Episodes per month
Public PodLume episodes featuring it, over the last year.
Show the data
| Month | Episodes |
|---|---|
| Nov 2025 | 0 |
| Dec 2025 | 0 |
| Jan 2026 | 0 |
| Feb 2026 | 0 |
| Mar 2026 | 0 |
| Apr 2026 | 0 |
| May 2026 | 0 |
| Jun 2026 | 0 |
| Jul 2026 | 1 |
| Aug 2026 | 0 |
| Sep 2026 | 0 |
| Oct 2026 | 0 |
What experts have said about MM120
2 statements · 1 positive · 1 neutral
MM120 may provide generalized-anxiety relief lasting 12 weeks.
“12 weeks of relief with GAD”
Open the episode · #875: The Random Show — Tim and Kevin Talk Retreats, Mortality, AI Predictions, Supplements, Rock Climbing at (Almost) 50, and Not Waiting for “Someday”Listen at 55:20
The minimum effective MM120 dose appears to be 100 micrograms.
“The minimum effective dose would be 100 micrograms.”
Open the episode · #875: The Random Show — Tim and Kevin Talk Retreats, Mortality, AI Predictions, Supplements, Rock Climbing at (Almost) 50, and Not Waiting for “Someday”Listen at 55:34
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.
Episodes
1 episode featuring MM120, newest first
